Navigation Links
OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
Date:8/29/2012

SAN DIEGO, Aug. 29, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its ImmunoPulse and NeoPulse therapies to treat solid tumor cancers, announced it will be presenting at the Rodman & Renshaw 2012 Annual Global Investment Conference in New York City.

Punit Dhillon, President and CEO of OncoSec, will deliver the Company presentation to conference attendees on Monday, September 10 at 3:15 PM ET in the Palm Room at the Waldorf Astoria Hotel. The presentation will also be webcast and can be viewed at this link: http://www.wsw.com/webcast/rrshq22/oncs

Mr. Dhillon said, "Presenting at the Rodman & Renshaw Global Investment Conference provides us an exciting opportunity to highlight our growing investment potential and leadership in the development of cancer therapies."

More than 300 public and private companies from around the world are registered to present in front of an audience of over 3,000 attendees. Newt Gingrich, 58th Speaker of the U.S. House of Representatives, will open the Conference as the Keynote Speaker on Monday, September 10. Conference registration details can be found at:
http://www.rodmanandrenshaw.com/conferences?id=176&link=registration

About OncoSec Medical Inc.

OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec's core technology is
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
8. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
9. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
10. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
11. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... DUBLIN , Nov. 26, 2014  Perrigo Company ... leading global provider of "Quality Affordable Healthcare Products®," today ... offering relating to the sale of 6,809,210 ordinary shares ... including the full exercise of the option to purchase ... Morgan Securities LLC and Barclays Capital Inc., as representatives ...
(Date:11/26/2014)... , Nov. 26, 2014   Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... Ph.D., President and CEO of Regulus, will present a ... Jaffray Healthcare Conference at the New York Palace Hotel ... The presentation will be webcast at the time of ...
(Date:11/26/2014)... Scott Steiger lives in St. ... an engineer for the past 20 years, he,s traveled extensively and ... He,s been to six of the seven continents. Travel is a ... http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 So ... pretty good idea of what,s required. His latest creation ...
Breaking Medicine Technology:Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Steiger Has Created the First Pill Case Specifically Designed For Travel 2
... by experts to be important for cervical cancer ... data from an,extended follow-up study show that GlaxoSmithKline ... generates sustained high levels of,neutralizing antibodies against the ... up to 6.4 years. This is the longest,duration ...
... American Society of Hypertension,s Twenty-Third ... Annual Scientific Meeting - A cumulative ... a regimen of BENICAR(R) (olmesartan medoxomil), and BENICAR HCT(R) (olmesartan ... normotension (< 120/80 mm Hg) (placebo:1.4%)., - Eight out of ...
Cached Medicine Technology:CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 2New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 3New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 4New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 5New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 7
(Date:11/28/2014)... An inventor and dental assistant from Kent, Wash., ... and it was almost impossible to reach. "This gave me ... , The patent-pending Access Light allows for easier use of ... the mouth, as well as avoids harm to the lips, ... use and clean, it also helps prevent cross-contamination. , The ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 A newly ... provides an overview of the influenza virus that will soon ... season. , The article begins with a brief explanation ... its symptoms. It reminds families that children under the age ... suffering from chronic diseases, such as heart and lung diseases, ...
(Date:11/28/2014)... "Most of my life, I have suffered from ... an inventor from Findlay, Ohio. "I thought that there had ... foot, which inspired me to invent this accessory." , She ... to support an injured foot. The sling makes it easier ... for crutches. The design redistributes weight so that the individual ...
(Date:11/28/2014)... TN (PRWEB) November 28, 2014 ARTAS ... Tennessee for the first time. PAI Medical Group hair ... will be performing a robotic hair transplant procedure in ... 9:00 A.M. , The first in Tennessee and one ... Medical Group now offers ARTAS robotic hair transplantation. Patients ...
(Date:11/28/2014)... Nipomo Family Dentistry , founded ... opened its doors at 195 N. Thompson St., Suite ... care like teeth cleanings, oral exams, fillings, implants and ... whitening (and Kor whitening), laser whitening, gum tissue treatment, ... Dentistry’s five-person team also takes a philanthropic approach to ...
Breaking Medicine News(10 mins):Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2Health News:First in Tennessee - PAI Medical Group Announces ARTAS - The World’s Most Advanced Medical Robot Used for Hair Transplant Surgery 2Health News:Nipomo Family Dentistry Opens New Dental Office in Nipomo 2Health News:Nipomo Family Dentistry Opens New Dental Office in Nipomo 3
... choice of drug for patients suffering from prostate cancer may ... the Scottish Medicines Consortium (SMC) is of the view that ... much effect on prostate cancer making it an expensive not ... the drug feel that the drug had shown very good ...
... of the main causes of tooth loss worldwide and ... extractions (those with periodontal disease lost 2.8 teeth versus ... has now been found out from research that certain ... than others. ,The study analyzed the effects ...
... sinus tumors can be removed through the nose using endoscopy ... ,With this approach, doctors use tiny scopes and ... a device that pulverizes and suctions. At points where the ... and a diamond drill is used to eliminate tumor cells ...
... appears in the October issue of the journal ... early exposure to severe hypoglycemia during development negatively ... is a significant and relatively common complication of ... Repeated severe hypoglycemia has been reported to reduce ...
... Minister Anbumani Ramadoss has said that the government is very ... plans to take several steps to check female foeticide, which ... Ramadoss said that there were plans to set up surveillance ... practice that prevails on a large scale in the country. ...
... new research shows that in Children with neurological ... respiratory failure ,if they're hospitalized with influenza.// ... Journal of the American Medical Association, are based on ... influenza at The Children's Hospital of Philadelphia over four ...
Cached Medicine News:Health News:Nine Major Culprits For Tooth Loss Identified By Researchers 2Health News:Nine Major Culprits For Tooth Loss Identified By Researchers 3Health News:Novel Technique For Management Of Inverted Papilloma Of Frontal Sinus 2Health News:Severe Hypoglycemia And Spatial Memory In Children With Type 1 Diabetes 2
... WideBiter Punch series facilitates fast and effective ... smooth, anatomically shaped meniscal rim. The flat, ... to access even the tightest joint spaces. ... Inc., 20 years of engineering experience in ...
... fast and effective resection of meniscal tears ... rim. The flat, crescent-shaped tip has an ... tightest joint spaces. Made in the U.S. ... engineering experience in arthroscopy hand instrument design ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
Medicine Products: